Her experience wasn’t unusual. When gastroenterologist Bruce Sands of the Icahn School of Medicine at Mount Sinai in New York City started practicing 30 years ago, he says, large numbers of his IBD patients couldn’t be helped. But much has changed, he says, especially in the past 10 years. There are far more possible—and precise—medications for the more than two million American adults and more than 100,000 children and adolescents with colitis or the other major form of IBD, Crohn’s disease.